文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

癌症患者 FACT 和 EQ-5D 量表效用评分的比较。

Comparison of FACT- and EQ-5D-based utility scores in cancer.

机构信息

Second City Outcomes Research, Oak Park, IL 60302, USA.

出版信息

Value Health. 2012 Mar-Apr;15(2):305-11. doi: 10.1016/j.jval.2011.11.029. Epub 2012 Feb 2.


DOI:10.1016/j.jval.2011.11.029
PMID:22433762
Abstract

OBJECTIVE: Although utility-based algorithms have been developed for the Functional Assessment of Cancer Therapy (FACT), their properties are not well known compared with those of generic utility measures such as the EQ-5D. Our objective was to compare EQ-5D and FACT preference-based scores in cancer patients. METHODS: A retrospective analysis was conducted on cross-sectional data collected from 472 cancer patients who completed both FACT-General and the EQ-5D. Preference-based scores were calculated by using published scoring functions for the EQ-5D (Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108; Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005;43:203-20) and FACT (Dobrez D, Cella D, Pickard AS, et al. Estimation of patient preference-based utility weights from the Functional Assessment of Cancer Therapy-General. Value Health 2007;10:266-72; Kind P, Macran S. Eliciting social preference weights for Functional Assessment of Cancer Therapy-Lung health states. Pharmacoeconomics 2005;23:1143-53; Cheung YB, Thumboo J, Gao F, et al. Mapping the English and Chinese versions of the Functional Assessment of Cancer Therapy-General to the EQ-5D utility index. Value Health 2009;12:371-6). Scores were compared on the basis of clinical severity by using Eastern Cooperative Oncology Group performance status ratings by physicians and patients. Relative efficiency of each scoring function was examined by using ratios of F statistics. RESULTS: Mean scores for the overall cohort were lowest when using Kind and Macran's FACT UK societal algorithm (0.55, SD 0.09) and highest when using Dobrez et al.'s FACT US patient algorithm (0.83, SD 0.08). Mean difference scores associated with clinical severity, when extrapolated to quality-adjusted life-years (QALYs), had a range of 0.18 QALYs gained using FACT (Kind and Macran) to 0.45 QALYs gained using the EQ-5D (Dolan). However, relative efficiencies suggested that FACT (Kind and Macran) scores may provide greater statistical power to detect significant differences based on clinical severity. CONCLUSIONS: We found important differences in utilities scores estimated by each algorithm, with FACT-based algorithms tending to underestimate the QALY benefit compared with algorithms based on the EQ-5D. These differences highlight some of the challenges in using disease-specific preference-based measures for decision making despite potentially more relevant disease-specific content.

摘要

目的:虽然已经为癌症疗法的功能性评估(FACT)开发了基于效用的算法,但与通用效用测量(如 EQ-5D)相比,它们的特性尚不清楚。我们的目的是比较癌症患者的 EQ-5D 和 FACT 偏好得分。

方法:对来自 472 名同时完成 FACT-General 和 EQ-5D 的癌症患者的横断面数据进行回顾性分析。使用发表的 EQ-5D 评分函数(Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108; Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005;43:203-20)和 FACT(Dobrez D, Cella D, Pickard AS, et al. Estimation of patient preference-based utility weights from the Functional Assessment of Cancer Therapy-General. Value Health 2007;10:266-72; Kind P, Macran S. Eliciting social preference weights for Functional Assessment of Cancer Therapy-Lung health states. Pharmacoeconomics 2005;23:1143-53; Cheung YB, Thumboo J, Gao F, et al. Mapping the English and Chinese versions of the Functional Assessment of Cancer Therapy-General to the EQ-5D utility index. Value Health 2009;12:371-6)计算偏好得分。根据医生和患者的东部合作肿瘤学组表现状态评分,基于临床严重程度对评分进行比较。通过 F 统计量的比值检查每个评分函数的相对效率。

结果:总体队列的平均得分最低的是 Kind 和 Macran 的 FACT UK 社会算法(0.55,SD 0.09),最高的是 Dobrez 等人的 FACT US 患者算法(0.83,SD 0.08)。当外推至质量调整生命年(QALY)时,与临床严重程度相关的平均差异评分范围为 0.18 QALY 获益(FACT(Kind 和 Macran))至 0.45 QALY 获益(Dolan 的 EQ-5D)。然而,相对效率表明,FACT(Kind 和 Macran)评分可能基于临床严重程度提供更大的统计能力来检测显著差异。

结论:我们发现每个算法估计的效用得分存在重要差异,基于 FACT 的算法与基于 EQ-5D 的算法相比,往往低估了 QALY 获益。这些差异突出了尽管具有潜在更相关的疾病特异性内容,但使用特定于疾病的偏好测量方法进行决策时面临的一些挑战。

相似文献

[1]
Comparison of FACT- and EQ-5D-based utility scores in cancer.

Value Health. 2012-2-2

[2]
Mapping the English and Chinese versions of the Functional Assessment of Cancer Therapy-General to the EQ-5D utility index.

Value Health. 2008-9-9

[3]
Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries.

Value Health. 2009

[4]
Mapping the FACT-P to the preference-based EQ-5D questionnaire in metastatic castration-resistant prostate cancer.

Value Health. 2014-3

[5]
The validity of EQ-5D US preference weights in liver transplant candidates and recipients.

Liver Transpl. 2009-1

[6]
Comparison of contemporaneous EQ-5D and SF-6D responses using scoring algorithms derived from similar valuation exercises.

Value Health. 2014-5-14

[7]
Comparison of Health State Utility Measures in Patients With Head and Neck Cancer.

JAMA Otolaryngol Head Neck Surg. 2015-8

[8]
Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.

Value Health. 2012-11-4

[9]
Responsiveness of EQ-5D utility indices in alcohol-dependent patients.

Drug Alcohol Depend. 2008-1-1

[10]
Validation and comparison of EuroQol and short form 6D in chronic prostatitis patients.

Value Health. 2010-4-15

引用本文的文献

[1]
Health Utility Survival for Randomized Clinical Trials: Extensions and Statistical Properties.

Stat Med. 2025-8

[2]
Development of algorithms to estimate the EQ-5D-5L from the FACT-L in patients with lung cancer: a mapping study.

Qual Life Res. 2024-3

[3]
A head-to-head comparison of the measurement properties of EQ-5D-3L and EQ-5D-5L in Chinese family caregivers of cancer patients.

Support Care Cancer. 2023-12-7

[4]
Dynamic changes in quality of life, psychological status, and body image in women who underwent a mastectomy as compared with breast reconstruction: an 8-year follow up.

Breast Cancer. 2023-3

[5]
Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors.

CNS Drugs. 2022-5

[6]
Collection of cancer Patient Reported Outcome Measures (PROMS) to link with primary and secondary electronic care records to understand and improve long term cancer outcomes: A protocol paper.

PLoS One. 2022

[7]
Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma.

J Neurooncol. 2022-2

[8]
Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives.

Cancers (Basel). 2021-12-29

[9]
Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis.

Pharmacoecon Open. 2021-9

[10]
Treating the patient and not just the cancer: therapeutic burden in prostate cancer.

Prostate Cancer Prostatic Dis. 2021-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索